Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Depreciation & Amortization (CF) (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $896000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 13.26% to $896000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2025, down 25.63% year-over-year, with the annual reading at $3.9 million for FY2025, 25.63% down from the prior year.
  • Depreciation & Amortization (CF) hit $896000.0 in Q4 2025 for Coherus Oncology, down from $966000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.5 million in Q3 2024 to a low of $767000.0 in Q1 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $1.0 million across 5 years, with a median of $924500.0 in 2021.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 72.3% in 2024 and later tumbled 37.64% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $836000.0 in 2021, then increased by 25.6% to $1.0 million in 2022, then increased by 1.24% to $1.1 million in 2023, then dropped by 2.82% to $1.0 million in 2024, then dropped by 13.26% to $896000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CHRS at $896000.0 in Q4 2025, $966000.0 in Q3 2025, and $1.0 million in Q2 2025.